Background: Cardiovascular diseases (CVDs) are more frequent in multiple sclerosis (MS) patients when compared to controls. In particular, CVDs are linked with higher accumulation of lesions and advanced brain atrophy. Objective: To investigate whether CVDs contribute to accelerated lesion accumulation and brain atrophy over 5 years in patients with MS. Methods: 194 MS patients and 43 controls without neurologic disease were followed for 5 years. Full physical, neurological evaluation, and structured questionnaire investigating CVD and risk factors (hypertension, hyperlipidemia, heart disease, smoking, diabetes, obesity/overweight) were collected using interview-based questionnaire and further cross-reference with electronic medical records. Lesion and brain atrophy outcomes were assessed with 3T MRI. ANCOVA adjusted for age, gender, and disease duration were used accordingly. False discovery rate correction was performed using BenjaminiHochberg correction. Results: Patients with diagnosis of heart disease showed higher white matter and whole brain volume loss compared to those without (À4.2% vs. À0.7%, P = 0.01 and À3.4% vs. À1.6%, P = 0.01, respectively). The percentage lateral ventricle volume change in MS patients with hypertension was higher compared to non-hypertensive patients (24.5% vs. 14.1%, P = 0.05). Hyperlipidemia, smoking, and obesity/overweight were not associated with progression of MRI-derived outcomes. CVDs did not contribute to larger lesion volume accrual over the 5-year period. The presence of CVDs was not associated with MRI-derived changes in the controls. Conclusions: Hypertension and heart disease contribute to advanced brain atrophy in MS patients. CVDs did not contribute to additional lesion accrual. CVD comorbidities in MS patients may contribute to neurodegenerative tissue injury that can be detected with brain MRI.
Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study 
Introduction
Multiple sclerosis (MS) is an autoimmune inflammatory and neurodegenerative disease of the central nervous system (CNS). Accumulating body of evidence points to a complex interplay of genetic, vascular, and environmental factors in the risk and severity of the disease [1] .
Regardless of the disease-initiating factors, presence of autoimmune, psychiatric, and cardiovascular diseases (CVD) has been increasingly associated with worse disease presentation and poorer long-term outcomes [2, 3] . For example, a nationwide study in Denmark that followed MS patients from 1980-2005 revealed lower occurrence of CVD comorbidities preceding MS, but higher prevalence after the MS diagnosis [4] . This suggests that there might be a common etiological mechanism in which the onset of MS produces a trigger for vascular comorbidity or that the vascular comorbidities directly arise from clinically active MS [4] .
A recent study utilizing electronic medical records at a tertiary MS referral center showed that the presence of hypertension, diabetes, and obstructive lung disease, but not hyperlipidemia had an independent and cumulative impact on clinical disability measures [5] . A large cross-sectional study showed that the presence of one or more CVD or risk factors including hypertension, heart disease, diabetes, hyperlipidemia, obesity or smoking are associated with an increase in lesion burden and lower brain volumes [6] . The detrimental effect of CVDs on the brain volume loss was not detected within the age-and sex-matched control group within that study. Furthermore, a longitudinal study corroborated the cross-sectional association of vascular risk factors and lower brain volume, and showed that the effect was already present in early MS [7] . However, the same study did not detect accelerated brain volume loss over 42 months of follow-up in MS patients with presence of vascular risk factors.
Therefore, we aimed to determine the influence of CVD over a 5-year follow-up period and in a larger sample of MS patients, and to assess their association with clinical and MRI outcomes of disease severity.
Materials and methods

Study population
The MS patients and individuals without neurological disease that were included in this analysis were enrolled as participants in a prospective cardiovascular, environmental, and genetic risk factors in MS patients (CEG-MS study) [8] . The baseline enrollment occurred within the period of 2009-2013 and subjects returned for a follow-up visit in the period of 2014-2017 after mean of 5.4 years. The inclusion criteria for the study were: (i) baseline and follow-up 3T MRI examination performed within 30 days of the clinical assessment using the same, standardized imaging protocol, (ii) baseline age range of 18 to 75 years, and (iii) being a healthy individual without current nor past neurological disease, or (iv) MS patients defined by the 2010-revised McDonald criteria [9] . The participants were not eligible for the study if they had clinically-diagnosed relapse or steroid treatment within 30 days prior of enrollment, were pregnant, or nursing. The study was approved by University at Buffalo Institutional Review Board and participants signed the written consent at both visits. The demographic and clinical data collection is provided in detail in the Appendix S1.
MRI acquisition and analysis
Baseline and follow-up brain scans (average follow-up time of 5.4 years) were acquired on a same 3T GE Signa Excite HD 12.0 Twin Speed 8-channel scanner (General Electric, Milwaukee, WI, USA) using an 8-channel head and neck (HDNV) coil. There were no MRI software or hardware changes over the follow-up. The MRI sequences consisted of: (i) 2D multi-planar dual fast spin-echo (SE) proton density (PD) and T2-weighted images (WI): (ii) 2D SE T1-WI:; (iii) FluidAttenuated Inversion Recovery (FLAIR) and (iv) 3D high resolution T1-WI using a fast, spoiled, gradient echo with magnetization-prepared inversion recovery pulse (IR-FSPGR). The details of the sequence parameters were previously described [6] .
The MRI analysis included computation of T2-and T1-lesion volume (LV), which was assessed using semiautomated edge detection contouring/thresholding technique. Normalized volumes of the whole brain (WBV), white matter (WMV), gray matter (GMV), and lateral ventricular volume (LVV) were obtained with SIENAX software (version 2.6; FMRIB, Oxford, UK) [10] . Prior to the volumetric segmentation, lesion filling technique was utilized to reduce the impact of T1 hypointensities. The percentage changes of the WBV, WMV, GMV, and LVV over the follow-up were calculated using SIENA (FMRIB, Oxford, UK) [10] and SIENAX multi-time-point algorithms [11] .
Statistical analysis
All statistical analyses were performed with SPSS (IBM, Armonk, NY, USA). Patients were divided based on the baseline status of hypertension, hyperlipidemia, heart disease, diabetes, smoking history, and BMI classification. For demographic and clinical characteristic, Chi-square test, Student's t-test, and nonparametric Mann-Whitney test were used accordingly. For comparison of the MRI-derived lesion and volumetric differences between patients with and without CVD or risk factors, Student's t-test and analysis of covariance (ANCOVA), adjusted for age, gender, and disease duration, were used. Only ANCOVA-adjusted P-values are presented. Both sets of analysis (cross-sectional and longitudinal) were false discovery rate corrected for multiple comparisons, using BenjaminiHochberg correction at alpha 0.05 level, which was considered statistically significant using two-tailed tests.
Results
Demographic and clinical characteristics of the population
The demographic and clinical characteristics of all 194 MS patients and 43 individuals without neurological disease are shown in Table 1 . The MS population consisted of 14.9% clinically isolated syndrome (CIS) patients, 59.8% relapsing-remitting (RRMS), and 25.3% progressive (PMS) patients. The PMS group had 42 secondary-progressive (SP) and seven primaryprogressive (PP) MS patients. The patients were on average 46.7 years old, had mean disease duration of 13.6 years, and 143 (73.7%) patients were female. The baseline median EDSS score was 2.5 (interquartile range 1.5-4.5) and over the follow-up period it increased to median EDSS score of 3.0 (interquartile range 1.5-5.5). The mean absolute change was 0.43 EDSS points. Detailed description of the prevalence and treatment of the CVDs present within the healthy control (HC) and MS population is provided in the Appendix S1. 
22 (75.9) 6 (100) 0.311 Hypertension therapy at follow-up, n (%) 42 (100) 10 (100) 1.000 Heart disease therapy at baseline, n (%) 2 (10.5) 2 (100) 0.029 Heart disease therapy at follow-up, n (%) 5 (17.2) 2 (66.7) 0.049 Hyperlipidemia therapy at baseline, n (%) 18 (66.7) 7 (100) 0.151 Hyperlipidemia therapy at follow-up, n (%) 45 (100) 10 (100) 1.000
All P-values were derived using v2-test, Fisher's exact test, Student's t-test, and Mann Whitney test as appropriate. P < 0.05 based on twotailed tests was considered statistically significant. Significant values (P < 0.05) are shown in bold; The category of other DMTs included patients treated with mitoxantrone [1] , intravenous immunoglobulins [2] and azathioprine [1] ; EDSS, Expanded Disability Status Scale; IQR, interquartile range; CIS, clinically isolated syndrome; RRMS, relapsing-remitting multiple sclerosis; PMS, progressive multiple sclerosis; BMI, body mass index; DMT, disease-modifying therapy. Data are given as n (%), mean (SD) and median (interquartile range).
Associations between CVD and MRI outcomes
The baseline and longitudinal brain volumes for both the MS patients and HCs are shown in the Table S1 . The age-matched HCs had significantly smaller T2-LV and larger baseline brain volumes when compared to the MS patients (T2-LV, WBV, WMV, GMV and LVV; all P < 0.01). The MS subgroups had greater annualized brain volume loss when compared to the HCs measured as WBV (RRMS>PMS>HCs%CIS, one-way ANOVA, P = 0.023) and WMV (RRMS> CIS%HC>PMS, one-way ANOVA, P = 0.046). After correcting for the significant differences in age, there were no differences in longitudinal volume changes across the three MS subgroups. PMS had the greatest GMV loss and LVV enlargement, whereas RRMS had greatest WBV and WMV loss. Similarly, the brain volumes from MS patients and HCs with and without at least one CVD are shown in the Table S2 . All significant associations between the aforementioned CVDs and their potential combinations with MRI-derived outcome measures are shown in Table 2 . After controlling for age, sex and disease duration, hypertension was significantly associated with greater increase in LVV over the follow-up period (24.5% vs. 14.1%, P = 0.05). There were additional significant associations between presence of heart disease and higher longitudinal WMV and WBV loss (À4.2% vs. À0.7%, P = 0.01 and À3.4% vs. À1.6%, P = 0.01, respectively). The baseline GMV and WMV differences between patients with and without heart disease did not survive the multiple comparison correction (P = 0.063 and P = 0.066, respectively). An effect of hyperlipidemia was not detected with any of the MRI-derived outcomes.
Other significant associations were seen between MS patients with heart disease and BMI>25 with decreased baseline GMV (771.7 ml vs. 722.8 ml, P = 0.045) and greater WMV and WBV loss over the follow-up (À5.3% vs. À0.7%, P = 0.018 and À3.9% vs. À1.6%, P = 0.007, respectively), and MS patients with heart disease and smoking history with greater WMV and WBV loss over the follow-up (À5.3% vs. À0.7%, P = 0.02 and À4.1% vs. À1.6%, P = 0.01, respectively). MS patients with the combination of heart diseases, BMI>25 and smoking history had greater WMV and WBV loss over the follow-up Cardiovascular diseases are diabetes, hypertension, heart disease or hyperlipidemia, whereas cardiovascular risk factors are smoking and BMI higher than 25; All P-values were derived using analysis of covariance (ANCOVA) adjusted for sex, age and disease duration. Significant values (P < 0.05) are shown in bold; CVD, cardiovascular disease; BMI, body mass index; LV, lesion volume; WBV, whole brain volume; WMV, white matter volume; GMV, gray matter volume; LVV, lateral ventricular volume; D, change over 5 years; a Only significant, before BenjaminiHochberg multiple correction analysis, are shown. Due to the small number of patients with diabetes, the effect of diabetes diagnosis on brain volume was not examined.
(À5.6% vs. À0.7%, P = 0.01 and À4.3% vs. À1.7%, P = 0.003, respectively).
When identical analyses were performed within the matched control population, no significant CVD effect on MRI-derived volumes was detected (data not shown). Similarly, the presence of CVDs in MS patients did not contribute to an additional T2 lesion development over the 5-year follow-up.
Post-hoc analysis of demographic and clinical characteristics of MS patients with and without CVDs
Tables S3 and S4 summarize the demographic and clinical characteristics of the patient groups at baseline, according to the presence or absence of hypertension, heart disease, hyperlipidemia, smoking history, and BMI. The only clinical effect of any CVD or CV risk factors was seen between MS patients who had history of smoking vs. those who did not. The annualized relapse rate was higher in "ever smokers" compared to "never smokers" (0.25 vs. 0.1, P = 0.018).
Discussion
This 5-year longitudinal study is one of the first to show that hypertension and heart disease contribute to accelerated central, WB, and WM atrophy in MS patients. However, during the study period of 5.4 years, the increased accumulation of brain atrophy did not result in disability progression. In this cohort, the significant changes within the combination of CVDs were mainly driven by the presence of heart disease and hypertension and their effect on WMV and WBV loss and ventricular enlargement.
The study confirms previously reported cross-sectional associations between single and multiple CVDs and CV risk factors, and worse MRI outcomes in MS patients [6] . A similar longitudinal study also showed that presence of at least one vascular risk factor was associated with decreased brain volumes in group of early MS patients, measured at both the baseline and follow-up MRI examinations [7] . However, in comparison to the findings from the present study, Pichler et al. failed to show any differences regarding the temporal change of the brain volume measures [7] . The discrepancy between the two studies might be explained by the longer follow-up period in our study when compared to the one used in the previous study (5.4 vs. 3.5 years) and by a nearly 2.5 times larger MS cohort (194 vs. 82 patients). In addition, their main analyses involved dichotomous separation of the MS patients (presence or absence of vascular risk factors) with only hypertension, hyperlipidemia, and smoking status being evaluated. On the other hand, we were able to examine the effect of each comorbidity, both individually and cumulatively.
Hypertension has been established as one of the most consequential CVDs in MS patients. A 3-year longitudinal study showed that hypertension, diabetes, and obstructive lung disease, but not hyperlipidemia, contributed to worsening of walking speed, depression, and disability [5] . Previous studies have also shown that hypertension is associated with increased risk of reaching higher levels of disability [12] . Apart from the synergistic effect with MS-associated brain atrophy, hypertension has been associated with development of brain lesions, brain atrophy, and decreased cognition in otherwise healthy population [13, 14] . Therefore, the American Heart Association (AHA) and the American College of Cardiology (ACC) updated the blood pressure cutoffs, lowering them from 140/90 mmHg to 130/ 80 mmHg [15] . This change will cause an increase in the hypertension prevalence and the greatest change would be seen among the younger adults (doubling among women and tripling among men <45 years) [15] . As we used clinical diagnosis that was established before this change in the hypertension definition, some of the potential hypertensive effect might have been present within our non-hypertensive group and thus limiting the strength of the analysis.
Moreover, this study showed that the presence of heart disease as a comorbidity in MS patients was associated with more advanced WM and WB atrophy. These results have to be interpreted with caution, given the lower treatment rate observed in the MS group, a potential bias that could have resulted in greater CVD-derived brain pathology. The prevalence of heart disease in the MS group (9.8%) was somewhat higher than the 5% prevalence reported in a recent meta-analysis [16] . Despite the relatively low study sample size, the incidence of CVDs within MS patients suggested higher risk of chronic heart failure (CHF) and heart attack but lower for cardiac valvar disease and arrhythmias [16] . Three population-based studies showed a similar two-fold increase in CHF in MS patients compared to a matched healthy population [16] . Additionally, within the 5-year period, we were able to detect 10 more cases of heart disease within the MS group, (5.1% increase in prevalence), whereas only one more control individual developed heart disease over the same amount of follow-up (2.3% increase in prevalence).
A common feature seen in this study is that the presence of hypertension and heart disease had a greater effect on acceleration of central, WB and WM atrophy, but not of the GMV. These findings are in line with the cardiovascular literature showing larger ventricular volumes in hypertensive and otherwise healthy subjects [17] . Quantitative analysis in aging population revealed a relationship between periventricular WM involvement (leukoaraiosis) and specific spatial brain atrophy associated with more advanced brain aging [18] . Similarly, patients with CHF tend to have greater LVV and higher atrophy of the subcortical gray matter structures [19, 20] .
The abnormal environment of dyslipidemia can potentially induce disease progression by affecting the integrity of the blood-brain barrier (BBB), increasing endothelial dysfunction, and causing persistent state of brain hypoperfusion [21] . A recent study described the unique lipid composition of the CNS endothelial cells and further recognized the lipids as the primary suppressors of the transcytotic trafficking [22] . Therefore, a lipid profile dysregulation could potentially lead to increased BBB trafficking and higher inflammatory activity. On that note, a prospective, multicentric study showed that MS patients with multiple comorbidities, and specifically presence of hyperlipidemia, had an increased relapse rate over subsequent 2 years [23] . Hyperlipidemia and altered lipid profile have been additionally associated with a higher rate of disability progression [24] . The relapse analysis of that study also demonstrated that being obese or having high levels of triglycerides (≥2.30 mmol/L) almost doubled the risk of relapse when compared to normal BMI or patients with normal triglyceride levels [24] . Multiple reports have further demonstrated lipid-mediated tissue damage in early MS and have shown an effect of high total cholesterol, high low-density lipoprotein cholesterol, and triglyceride levels on both inflammatory and neurodegenerative changes [25, 26] . In the present study, we did not show an independent effect of hyperlipidemia on the rate of brain atrophy. Previously mentioned 3-year prospective study corroborated the results and showed that hyperlipidemia does not contribute to worsening of clinical outcomes [5] . As our cohort was in their later years of the disease, the deleterious effect of the lipid dysregulation may have already occurred. Moreover, patients with a diagnosis of hyperlipidemia were significantly older, therefore, limiting the ability to distinguish the effects of aging versus CVD.
Smoking has been associated with both acceleration in time to progressive MS and worse MRI-derived outcome measures [27] [28] [29] . Reasons why we did not see differences between the ever/never smokers analysis in the current study might be due to the nature of the questionnaire used. As the smoking history of the patients was assessed regarding an overall smoking status in the past, the negative effect of smoking might be too far in the past to influence the development of lesions or brain atrophy during the study period. Previous studies have shown that persistent smoking after disease diagnosis, and not the history of smoking, contributes to the accelerated disease progression [30] . In particular, analysis showed difference in the age of the conversion to progressive MS in patients who quit smoking vs. the ones who continued, whereas this difference was not detected between patients who had ever vs. never smoked [30] .
The effect of the CVDs might also influence the disease progression in MS in an indirect way. A retrospective population-based study showed that out of 10 698 MS patients, half reported at least one comorbidity and as the number of comorbidities increased, the likelihood of DMT initiation decreased [31] . In our study population, the presence of one, two or three CVDs did not influence the use of DMTs. Within the North American Research Committee on Multiple Sclerosis database, the diagnosis of MS was significantly delayed in patients with presence of obesity, smoking, physical, or mental comorbidities [32] . Therefore, the delayed diagnosis due to presence of CVD comorbidities would lead to longer periods being not treated and potentially leaving detrimental MS activity uncontrolled. Moreover, similar nationwide study showed that presence of comorbidity has a significant negative effect on both MS mortality and delay in the MS diagnosis [33] .
The relatively small sample size of MS patients (n = 194) in the present study provides limited epidemiologic data on the cardiovascular comorbidities and constrained the detection of subtle independent changes caused by hyperlipidemia, smoking status, and obesity. As expected, CVDs were more prevalent in older MS patients, thus limiting our interpretations of the direct volumetric comparisons. Therefore, larger age-and sex-matched studies can provide further insight on the effect size on MRI-derived volumetric outcomes in patients with vascular comorbidities. Although we did not demonstrate an effect of CVDs in the HCs, there was a small sample size and relatively short follow-up time which might have influenced our analysis. Previous reports of healthy population have demonstrated long-term effect of CVDs in accumulating brain pathology. Despite previous reports of decreased benefit of DMT in comorbid patients (e.g. decreased interferon response in smokers), relatively limited sample size did not allow further analysis of the effect of comorbidity on the DMT efficacy [34] . Based on our results, clinical studies and treatment trials should be mindful of the CVD effect in MS patients. Potential uneven CVD distribution may influence the study findings and provide important bias.
In conclusion, the presence of hypertension and heart disease contributed to advanced brain atrophy in MS patients over 5-year follow-up period. Concurrence of MS and CVDs may contribute to additional neurodegenerative injury that can be detected with MRI. This adverse effect of CVDs was not detected within the same period length in the matched control individuals. Careful cardiovascular assessment, monitoring, and treatment of MS patients might be warranted and will potentially improve their overall disease outcome.
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